An ECLIPSE View of Alpha-1 Antitrypsin Deficiency.

Area of Science:

• Pulmonology and Respiratory Medicine
• Clinical Trial Design
• Genetics and Biomarkers

Background:

• Chronic obstructive pulmonary disease (COPD) is a major global health burden, projected as the third leading cause of death in 2020.
• Understanding COPD's complexity and progression is crucial for effective clinical trial endpoints and patient management.

Purpose of the Study:

• To define outcomes for clinical trial endpoints in COPD patients using the ECLIPSE study cohort.
• To characterize COPD heterogeneity, exacerbation patterns, and factors influencing disease progression.

Main Methods:

• Observational study design (ECLIPSE) involving a cohort of individuals with COPD.
• Analysis of lung function decline, emphysema progression via CT scans, and identification of genetic factors and biomarkers.
• Longitudinal data collection to assess disease stability and progression.

Main Results:

• Detailed description of COPD heterogeneity and the stability of exacerbation phenotypes.
• Identification of factors associated with progressive lung function decline and emphysema.
• Discovery of genetic factors and biomarkers linked to COPD and disease progression.

Conclusions:

• The ECLIPSE study provides valuable insights into COPD's multifaceted nature and progression.
• Results can inform the development of surrogate endpoints for clinical trials in COPD.
• Findings contribute to understanding COPD, particularly in relation to alpha-1 antitrypsin deficiency.